Patents by Inventor Thomas Ondet

Thomas Ondet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for evaluating the efficacy of a composition in reducing the effects of cancer therapeutics on skin
    Patent number: 12174172
    Abstract: An epidermal tridimensional model exhibiting differentiating keratinocytes in a reconstituted stratum corneum model is disclosed. The model, which contains a cancer therapeutic at an amount effective to simulate chronic drug exposure, can be used to evaluate the potential of cancer therapeutics to produce skin related side effects. The method can also be used to evaluate the efficacy of a composition in reducing the effects of cancer therapeutics on skin.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: December 24, 2024
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Nicolas Joly-Tonetti, Thomas Ondet, Mario Monshouwer, Georgios N. Stamatas
  • USE OF BIOMARKERS TO EVALUATE THE EFFICACY OF A COMPOSITION IN REDUCING THE EFFECTS OF CANCER THERAPEUTICS ON SKIN
    Publication number: 20220057383
    Abstract: A method to evaluate the potential of cancer therapeutics to produce skin related side effects is disclosed. The method, which involves use of biological markers, can also be used to evaluate the efficacy of a composition in reducing the effects of cancer therapeutics on skin.
    Type: Application
    Filed: October 29, 2020
    Publication date: February 24, 2022
    Inventors: Thomas Ondet, Marius Monshouwer, Georgios N. Stamatas, Pierre-Francois Roux
  • Method for Evaluating the Efficacy of a Composition in Reducing the Effects of Cancer Therapeutics on Skin
    Publication number: 20210190761
    Abstract: An epidermal tridimensional model exhibiting differentiating keratinocytes in a reconstituted stratum corneum model is disclosed. The model, which contains a cancer therapeutic at an amount effective to simulate chronic drug exposure, can be used to evaluate the potential of cancer therapeutics to produce skin related side effects. The method can also be used to evaluate the efficacy of a composition in reducing the effects of cancer therapeutics on skin.
    Type: Application
    Filed: October 29, 2020
    Publication date: June 24, 2021
    Inventors: Nicolas Joly-Tonetti, Thomas Ondet, Mario Monshouwer, Georgios N. Stamatas